TG Therapeutics, Inc. NKB2.F Stock
TG Therapeutics, Inc. Price Chart
TG Therapeutics, Inc. NKB2.F Financial and Trading Overview
TG Therapeutics, Inc. stock price | 15.38 EUR |
Previous Close | 24.95 EUR |
Open | 24.01 EUR |
Bid | 24.07 EUR x 150000 |
Ask | 24.21 EUR x 150000 |
Day's Range | 24.01 - 24.01 EUR |
52 Week Range | 3.51 - 32.71 EUR |
Volume | 50 EUR |
Avg. Volume | 33 EUR |
Market Cap | 3.59B EUR |
Beta (5Y Monthly) | 2.09014 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0.28 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 59.88 EUR |
NKB2.F Valuation Measures
Enterprise Value | 3.49B EUR |
Trailing P/E | N/A |
Forward P/E | -10.484716 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 418.4552 |
Price/Book (mrq) | 121.26263 |
Enterprise Value/Revenue | 407.268 |
Enterprise Value/EBITDA | -21.462 |
Trading Information
TG Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 2.09014 |
52-Week Change | 621.99% |
S&P500 52-Week Change | 20.43% |
52 Week High | 32.71 EUR |
52 Week Low | 3.51 EUR |
50-Day Moving Average | 23 EUR |
200-Day Moving Average | 13.07 EUR |
NKB2.F Share Statistics
Avg. Volume (3 month) | 33 EUR |
Avg. Daily Volume (10-Days) | 25 EUR |
Shares Outstanding | 149.4M |
Float | 120.18M |
Short Ratio | N/A |
% Held by Insiders | 8.85% |
% Held by Institutions | 72.16% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1901.061% |
Gross Margin | 89.67% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -40.70% |
Return on Equity (ttm) | -170.41% |
Income Statement
Revenue (ttm) | 8.57M EUR |
Revenue Per Share (ttm) | 0.06 EUR |
Quarterly Revenue Growth (yoy) | 287.10% |
Gross Profit (ttm) | 2.52M EUR |
EBITDA | -162664000 EUR |
Net Income Avi to Common (ttm) | -168554000 EUR |
Diluted EPS (ttm) | -1.07 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 139.71M EUR |
Total Cash Per Share (mrq) | 1.01 EUR |
Total Debt (mrq) | 108.43M EUR |
Total Debt/Equity (mrq) | 395.26 EUR |
Current Ratio (mrq) | 2.93 |
Book Value Per Share (mrq) | 0.198 |
Cash Flow Statement
Operating Cash Flow (ttm) | -167383008 EUR |
Levered Free Cash Flow (ttm) | -109912248 EUR |
Profile of TG Therapeutics, Inc.
Country | Germany |
State | NC |
City | Morrisville |
Address | 3020 Carrington Mill Blvd. |
ZIP | 27560 |
Phone | 212 554 4484 |
Website | https://www.tgtherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 237 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Q&A For TG Therapeutics, Inc. Stock
What is a current NKB2.F stock price?
TG Therapeutics, Inc. NKB2.F stock price today per share is 15.38 EUR.
How to purchase TG Therapeutics, Inc. stock?
You can buy NKB2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for TG Therapeutics, Inc.?
The stock symbol or ticker of TG Therapeutics, Inc. is NKB2.F.
Which industry does the TG Therapeutics, Inc. company belong to?
The TG Therapeutics, Inc. industry is Biotechnology.
How many shares does TG Therapeutics, Inc. have in circulation?
The max supply of TG Therapeutics, Inc. shares is 157.38M.
What is TG Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
TG Therapeutics, Inc. PE Ratio is 54.94285600 now.
What was TG Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
TG Therapeutics, Inc. EPS is 0.28 EUR over the trailing 12 months.
Which sector does the TG Therapeutics, Inc. company belong to?
The TG Therapeutics, Inc. sector is Healthcare.